Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects - Concepedia

Concepedia

Publication | Closed Access

Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects

23

Citations

23

References

2008

Year

Heather‐Jane Au, Kamran Golmohammadi, Tallal Younis, Shailendra Verma, Stephen Chia, Konrad Fassbender, Philip Jacobs

Breast Cancer Research and Treatment

Node-positive Breast CancerBreast OncologyCost-effectiveness AnalysisOncologyMedicineDownstream EffectsBreast CancerPharmacotherapyCancer TreatmentPharmacology

References

	Year	Citations

Page 1